{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:54:54Z","timestamp":1793012094578,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.chest.2023.11.035","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T16:21:41Z","timestamp":1701102101000},"page":"1163-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Comparison of Pirfenidone and Nintedanib"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8887-150X","authenticated-orcid":false,"given":"John S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-2172","authenticated-orcid":false,"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-7798","authenticated-orcid":false,"given":"Hyun J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-5030","authenticated-orcid":false,"given":"Imre","family":"Noth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.chest.2023.11.035_bib1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2023.11.035_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","article-title":"Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis","volume":"22","author":"Belhassen","year":"2021","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.chest.2023.11.035_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12931-021-01857-y","article-title":"Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"22","author":"Marijic","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2023.11.035_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.581828","article-title":"Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study","volume":"7","author":"Cameli","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.chest.2023.11.035_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105803","article-title":"Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment","volume":"159","author":"Cerri","year":"2019","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2023.11.035_bib8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.11.035_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Hamada","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2023.11.035_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.chest.2023.11.035_bib11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial","volume":"325","author":"Martinez","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12931-020-1326-1","article-title":"Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial","volume":"21","author":"Anstrom","year":"2020","journal-title":"Respir Res"},{"issue":"14","key":"10.1016\/j.chest.2023.11.035_bib13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstrom","year":"2023","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.chest.2023.11.035_bib14","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs\u00a0placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial","volume":"324","author":"Wilson","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.chest.2023.11.035_bib15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.202106-1485OC","article-title":"Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: a multicenter, randomized, placebo-controlled study (SCENIC Trial)","volume":"205","author":"Martinez","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2023.11.035_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","article-title":"A\u00a0phase IIb randomized clinical study of an anti-alpha(v)beta(6) monoclonal antibody in idiopathic pulmonary fibrosis","volume":"206","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2023.11.035_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/resp.14116","article-title":"Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort","volume":"26","author":"Durheim","year":"2021","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12931-020-1315-4","article-title":"Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry","volume":"21","author":"Holtze","year":"2020","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.chest.2023.11.035_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03198-2020","article-title":"Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation","volume":"57","author":"Justet","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2023.11.035_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01797-2018","article-title":"Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials","volume":"54","author":"Noth","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2023.11.035_bib21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10554-022-02541-y","article-title":"Incremental prognostic value of arterial elastance in mild-to-moderate idiopathic pulmonary fibrosis","volume":"38","author":"Sonaglioni","year":"2022","journal-title":"Int J Cardiovasc Imaging"},{"issue":"153","key":"10.1016\/j.chest.2023.11.035_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0044-2019","article-title":"Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue","volume":"28","author":"Caminati","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"7","key":"10.1016\/j.chest.2023.11.035_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s11739-021-02651-w","article-title":"The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities","volume":"16","author":"Caminati","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib24","doi-asserted-by":"crossref","first-page":"e000782","DOI":"10.1136\/bmjresp-2020-000782","article-title":"Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis","volume":"8","author":"Wright","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"18","key":"10.1016\/j.chest.2023.11.035_bib25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2023.11.035_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00100-2019","article-title":"Vascular permeability in the fibrotic lung","volume":"56","author":"Probst","year":"2020","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.chest.2023.11.035_bib27","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/eurheartj\/ehl302","article-title":"Gas diffusion and alveolar-capillary unit in chronic heart failure","volume":"27","author":"Agostoni","year":"2006","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.chest.2023.11.035_bib28","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1161\/01.CIR.91.11.2769","article-title":"Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance","volume":"91","author":"Puri","year":"1995","journal-title":"Circulation"},{"issue":"3-b suppl","key":"10.1016\/j.chest.2023.11.035_bib29","first-page":"S5","article-title":"Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments","volume":"23","author":"Fleetwood","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.chest.2023.11.035_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1378\/chest.13-0844","article-title":"Predicting pulmonary fibrosis disease\u00a0course from past trends in pulmonary function","volume":"145","author":"Schmidt","year":"2014","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2023.11.035_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02151-2019","article-title":"FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change","volume":"55","author":"Nathan","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2023.11.035_bib32","article-title":"Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response","volume":"8","author":"Bowman","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.chest.2023.11.035_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1164\/rccm.202008-3093OC","article-title":"Blood transcriptomic predicts progression of pulmonary fibrosis and associates natural killer cells","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223058270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223058270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:57:14Z","timestamp":1717592234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223058270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0012369223058270"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.11.035","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Pirfenidone and Nintedanib","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}